GWS
ACRS icon

Glassman Wealth Services’s Aclaris Therapeutics ACRS Stock Holding History

Glassman Wealth Services’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16
Closed -$252 – 1894
2022
Q4 		$252 Hold
16
– – ﹤0.01% 1742
2022
Q3 		$0 Hold
16
– – ﹤0.01% 1621
2022
Q2 		$0 Buy
+16
New +$224 ﹤0.01% 1632

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Glassman Wealth Services's ACRS Position: Q1 2023 in Review

Glassman Wealth Services sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 16 shares — an estimated $252 sold.

Glassman Wealth Services first reported a position in ACRS in Q2 2022 and held it in 3 quarters. The position peaked at $252 in Q4 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • Glassman Wealth Services reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 16 Aclaris Therapeutics shares in Q1 2023, an estimated $252.
  • Glassman Wealth Services first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 3 quarters.
  • Glassman Wealth Services's Aclaris Therapeutics position peaked at $252 in Q4 2022.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Glassman Wealth Services's 13F filing for Q1 2023, filed 4 May 2023.